Xeris Biopharma Holdings (NASDAQ:XERS) told investors that it would be releasing its fourth quarter and full-year 2023 financial results before the US markets open on Wednesday, March 6, 2024.
Management will host a conference call at 8.30am Eastern Time to discuss the results and provide full-year 2024 guidance. Interested parties can register for the conference all here.
Xeris is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies.